Europe Acute Myeloid Leukemia Epidemiology and Patient Flow Analysis - 2017

Europe Acute Myeloid Leukemia Epidemiology and Patient Flow Analysis - 2017

Fore Pharma announced the results of its Acute Myeloid Leukemia patients study in a new report ‘Europe Acute Myeloid Leukemia Epidemiology and Patient Flow Analysis - 2017’. The report provides insights into Acute Myeloid Leukemia epidemiology, Acute Myeloid Leukemia diagnosed patients, and Acute Myeloid Leukemia treatment rate for EU5 pharmaceutical markets. The study measures key indicators such as prevalence of Acute Myeloid Leukemia derived from epidemiological analysis, percentage of patients diagnosed with Acute Myeloid Leukemia, and percentage of patients treated with a therapy.

The study helps executives estimate Acute Myeloid Leukemia market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Acute Myeloid Leukemia prevalence, Acute Myeloid Leukemia diagnosis rate, and Acute Myeloid Leukemia treatment rate for the period 2016 - 2025. The information is presented by leading geographies including Germany, France, Spain, Italy, and UK. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.

Key Features of the Report:

• Acute Myeloid Leukemia Patient Flow
• Acute Myeloid Leukemia Prevalence
• Acute Myeloid Leukemia Diagnosed Patients
• Acute Myeloid Leukemia Treated Patients